500 mg of NMN for 12 Weeks Changed Hair Follicle Maturation in 15 Japanese Women
Nicotinamide mononucleotide (NMN) has been marketed as a “longevity supplement” for years, but clinical attention has focused on metabolic health, insulin sensitivity and strength. Direct data on skin and hair have lagged. An early 2026 Japanese pilot study filled in part of that gap. Fifteen Japanese women aged 40 to 50 took 500 mg of NMN once daily for 12 weeks, and the researchers reported improvements in hair follicle maturation and scalp nutrient delivery.
Why “follicle maturation” matters
In hair-loss research, “follicle maturation” means resting (telogen) follicles transitioning to growth (anagen), with the anagen phase stable in length and depth. A core problem in female pattern hair loss and menopausal hair thinning is that follicles become shallower and shorter over time, producing thinner individual strands. It is not that new hair stops growing; the growing hair loses diameter and length.
The researchers measured follicle depth, scalp blood flow and nutrient-delivery markers around the follicle (glucose and amino acid supply). With only 15 participants, this is a pilot, but the fact that all three markers moved in the same direction is the interesting part. The physical environment around the follicle appears to be changing, not just a single surrogate endpoint.
How NAD+ reaches the follicle
NMN’s job inside the body is to raise NAD+ (nicotinamide adenine dinucleotide), a cofactor essential for mitochondrial energy production, sirtuin activation and DNA repair. Tissue NAD+ drops with age. Hair follicles during the anagen phase are among the most metabolically active structures in the body, burning through energy and dividing cells at high rates, so the hypothesis that low NAD+ limits anagen maintenance has been around for a while.
This pilot does not fully prove that hypothesis, but it does show that an orally bioavailable, commercially sold 500 mg dose of NMN can produce follicle-level change in humans. That opens a new lane for female hair thinning management, which has been dominated by topical minoxidil.
The 15 person ceiling
Fifteen participants, one country and 12 weeks are all real limitations. It is unclear how the placebo control was structured, whether the result replicates in different genetic backgrounds and whether effects persist past 6 months. Follow-up trials will settle those questions. The finding still matters because it gives many women who already take NMN a concrete answer to “what am I actually getting from this.”
A few things to check before adding it. The dose in this trial was 500 mg per day; commercial products range from 125 mg to 1000 mg per capsule, so label verification is essential. Long-term safety data are still accumulating, and the effect of raised NAD+ on tumor metabolism is not fully characterized, so anyone with a personal history of cancer or current cancer treatment should talk to a physician first. Check any vitamin B3 products you already take, since niacinamide and NMN both feed the NAD+ precursor pathway and stacking them without thought is unnecessary.